NCT01612871View on ClinicalTrials.gov

Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 27, 2012

Primary Completion Date

January 28, 2016

Study Completion Date

January 28, 2016

Conditions
Breast Cancer
Interventions
DRUG

Tamoxifen, Letrozole , Anastrozole, Exemestane

"Current first line metastatic hormone therapy treatment in hormone dependent breast cancer :~Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day"

Trial Locations (2)

31052

Institut Claudius REGAUD Toulouse, Toulouse

34298

Centre Val d'Aurelle - Paul Lamarque, Montpellier

All Listed Sponsors
lead

Institut Claudius Regaud

OTHER

NCT01612871 - Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer | Biotech Hunter | Biotech Hunter